ReviewProstaglandins & other lipid mediators2017
The novel lipid mediator PD1
Review in Prostaglandins & other lipid mediators, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Determining the half-life and turnover rate of EPA, n-3 docosapentaenoic acid, and DHA in humans using the natural abundance of carbon-13: a secondary analysis of a randomized clinical trial.The American journal of clinical nutrition · 2026Trial
- Assessing the Potential of an Enzymatically Liberated Salmon Oil to Support Immune Health Recovery from Acute SARS-CoV-2 Infection via Change in the Expression of Cytokine, Chemokine and Interferon-Related Genes.International journal of molecular sciences · 2024Trial
- Biology and Total Synthesis of n-3 Docosapentaenoic Acid-Derived Specialized Pro-Resolving Mediators.Molecules (Basel, Switzerland) · 2024Review
- Inhaled toxicants and pulmonary lipid metabolism: biological consequences and therapeutic interventions.Toxicological sciences : an official journal of the Society of Toxicology · 2023Article
- Stereoselective Synthesis, Pro-resolution, and Anti-inflammatory Actions of RvD5Journal of natural products · 2023Article
- N-3 Polyunsaturated Fatty Acids as a Nutritional Support of the Reproductive and Immune System of Cattle-A Review.Animals : an open access journal from MDPI · 2023Review
- The Use of Specialized Pro-Resolving Mediators in Biomaterial-Based Immunomodulation.Journal of functional biomaterials · 2023Review
- Targeting Angiogenesis via Resolution of Inflammation.Cold Spring Harbor perspectives in medicine · 2023Review
- Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.Biochemical pharmacology · 2023Review
- A combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome-like features in a mouse model.JADA foundational science · 2023Article
- Protectins: Their biosynthesis, metabolism and structure-functions.Biochemical pharmacology · 2022Review
- Stereoselective Synthesis, Configurational Assignment and Biological Evaluations of the Lipid Mediator RvD2Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.Annals of diagnostic pathology · 2022Article
- Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.Frontiers in immunology · 2022Review
- Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.Nature reviews. Nephrology · 2021Review
- A new synthetic protectin D1 analog 3-oxa-PD1Organic & biomolecular chemistry · 2021Article
- Stereoselective Synthesis and Structural Confirmation of the Specialized Pro-Resolving Mediator Resolvin E4.The Journal of organic chemistry · 2021Article
- Specialized Pro-resolving Lipid Mediators and Glial Cells: Emerging Candidates for Brain Homeostasis and Repair.Frontiers in cellular neuroscience · 2021Review
- Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?Nutrients · 2020Review
- The First Total Synthesis of the Lipid Mediator PD2Journal of natural products · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Resolvins, protectins and maresins are individual families of specialized pro-resolving mediators biosynthesized from the dietary n-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid. These enzymatically oxygenated polyunsaturated lipid mediators were first elucidated during the resolution phase of acute inflammation in animal models of self-limited inflammation. Specialized pro-resolving mediators display potent bioactions when administrated in vivo. Biosynthetic pathway studies have revealed that individual lipoxygenases and cyclooxygenase-2 converts eicosapentaenoic acid and docosahexaenoic acid into distinct families of the resolvins, protectins and maresins. Recently n-3 docosapentaenoic acid was found to be a substrate for the biosynthesis of several novel families of specialized pro-resolving mediators. One example is PD1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.